Pluribus Labs’s Amgen AMGN Stock Holding History

Pluribus Labs’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,260	Closed	-$283K	–	61
2021 Q4	$283K	Buy	+1,260	New	+$266K	0.3%	142

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pluribus Labs's AMGN Position: Q1 2022 in Review

Pluribus Labs sold out of Amgen (AMGN) in Q1 2022, closing a stake of 1,260 shares — an estimated $283K sold.

Pluribus Labs first reported a position in AMGN in Q4 2021 and held it in 1 quarter. The position peaked at $283K in Q4 2021. 2,337 funds tracked by Wall St. Rank hold AMGN as of Q1 2022.

Pluribus Labs reported no remaining Amgen position as of Q1 2022 after selling out during the quarter.
Pluribus Labs sold 1,260 Amgen shares in Q1 2022, an estimated $283K.
Pluribus Labs first reported a position in Amgen in Q4 2021 and held it in 1 quarter.
Pluribus Labs's Amgen position peaked at $283K in Q4 2021.
2,337 funds tracked by Wall St. Rank held Amgen as of Q1 2022.

Based on Pluribus Labs's 13F filing for Q1 2022, filed 16 May 2022.